December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
Baricitinib shows promise for treating alopecia areata with mild side effects.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
July 2026 in “Dermatology and Therapy” Alopecia areata in Brazil causes significant psychosocial impacts, with limited access to advanced treatments, especially in public healthcare.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
1 citations
,
July 2023 in “Cureus” Cetosomal minoxidil alone and with finasteride is effective and well-tolerated for hair loss treatment.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
April 2025 in “Acta Dermato Venereologica” Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.
October 2022 in “Journal of the ASEAN Federation of Endocrine Societies” GnRH-a or orchiectomy is more effective than anti-androgens for managing hormone levels in transgender women.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
October 2025 in “Dermatologica Sinica” A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.
August 2025 in “Clinical and Experimental Dermatology” Alopecia areata treatments often don't lead to lasting improvement.
May 2025 in “Journal of Cosmetic Dermatology” Cuticapil Stem Hair Serum improves hair growth and reduces shedding when added to minoxidil.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
June 2017 in “Journal of The American Academy of Dermatology” LED light helps hair follicle cells grow and prevents them from dying by activating certain cell pathways.
April 2026 in “Clinical and Experimental Dermatology” Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
December 2024 in “Value in Health” A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
August 2024 in “medRxiv (Cold Spring Harbor Laboratory)” Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
3 citations
,
May 2024 in “International Journal of Dermatology”